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Summary
 
Natural killer (NK) T cells are a lymphocyte subset with a distinct surface phenotype, an in-
variant T cell receptor (TCR), and reactivity to CD1. Here we show that mouse NK T cells
can recognize human CD1d as well as mouse CD1, and human NK T cells also recognize both
CD1 homologues. The unprecedented degree of conservation of this T cell recognition system
suggests that it is fundamentally important. Mouse or human CD1 molecules can present the
 
glycolipid 
 
a
 
-galactosylceramide (
 
a
 
-GalCer) to NK T cells from either species. Human T cells,
 
preselected for invariant V
 
a
 
24
 
 
 
TCR expression, uniformly recognize 
 
a
 
-GalCer presented by
either human CD1d or mouse CD1. In addition, culture of human peripheral blood cells with
 
a
 
-GalCer led to the dramatic expansion of NK T cells with an invariant (V
 
a
 
24
 
1
 
) TCR and
the release of large amounts of cytokines. Because invariant V
 
a
 
14
 
1
 
 and V
 
a
 
24
 
1
 
 NK T cells
have been implicated both in the control of autoimmune disease and the response to tumors,
our data suggest that 
 
a
 
-GalCer could be a useful agent for modulating human immune re-
sponses by activation of the highly conserved NK T cell subset.
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C
 
D1 molecules are 
 
b
 
2-microglobulin (
 
b
 
2m)–asso-
ciated
 
1
 
 transmembrane proteins that are related to
MHC-encoded antigen presenting molecules. Despite their
association with 
 
b
 
2m, comparisons of primary sequences
demonstrate that CD1 molecules are almost as closely re-
lated to class II molecules as they are to class I molecules
(1). Therefore, CD1 molecules probably diverged from
these other antigen presenting molecules early in vertebrate
evolution, around the time of the class I–class II diver-
gence. CD1 molecules are distinguished from the MHC-
encoded classical class I and class II molecules by their lack
of polymorphism. Of the five human 
 
CD1
 
 genes, protein
products have been identified for the CD1a, -b, -c, and -d
isoforms (2). The CD1 isoforms are themselves quite diver-
gent, although CD1a, -b, and -c are more closely related to
one another in their amino acid sequences than to CD1d
(1, 3). Only two CD1 genes, 
 
CD1d1
 
 and 
 
CD1d2
 
, have
been identified in mice. They are highly related to one an-
other and are most similar to human 
 
CD1d
 
 in sequence (4).
However, there is not an extraordinarily high degree of
conservation between the mouse CD1 (mCD1) and hu-
man CD1d (hCD1d) homologues. The overall percentage
of sequence identity between the hCD1d and mCD1
polypeptides in the antigen binding region is 60.4% for the
 
a
 
1 domain and 62.4% for the 
 
a
 
2 domain (1, 5).
One of the properties shared by mCD1 and hCD1d
molecules is their ability to be recognized by NK T cells
(6–11). Recently, much interest has been focused upon the
NK T cell subpopulation on account of its ability to
quickly produce large amounts of cytokines, suggesting a
potential for these T cells to regulate immune responses.
The majority of mouse NK T cells use mainly the V
 
b
 
8.2,
V
 
b
 
7, or V
 
b
 
2 chain paired with an invariant V
 
a
 
14J
 
a
 
281
rearrangement (12). The human counterpart of the mouse
NK T cells also expresses a restricted TCR repertoire,
including a homologous, invariant V
 
a
 
24 rearrangement
paired with V
 
b
 
11, the human homologue of mouse V
 
b
 
8
(13–15). NK T cells in both species are autoreactive in
vitro for CD1 molecules, in the absence of exogenous anti-
gen. In addition to TCR repertoire and CD1 autoreactiv-
 
1
 
Abbreviations used in this paper:
 
 
 
a
 
-GalCer, 
 
a
 
-galactosylceramide; 
 
b
 
2m,
 
b
 
2-microglobulin; hCD1d, human CD1d; mCD1, mouse CD1.
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ity, NK T cells from both species resemble each other in
several additional ways, including expression of intermedi-
ate TCR levels, expression of CD4 or the absence of both
CD4 and CD8, expression of cell surface proteins charac-
teristic of memory or activated T cells (16), and the pres-
ence of NK receptors, particularly NK1.1 (CD161) in mice
(17, 18) and its homologue, NKRP1, in humans (11, 16).
Despite their relatively restricted TCR repertoire, a mi-
nority of NK T cells lack V
 
a
 
14 expression. Moreover,
V
 
a
 
14 can be paired in the mouse with several different
V
 
b
 
s (19), and the V
 
b
 
 rearrangements expressed by NK T
cells have junctional diversity (12). The combination of
these three factors allows for some diversity in the antigen
receptors expressed by the NK T cell population, and the
results from recent studies in the mouse indicate that
mCD1 autoreactive T cells are in fact heterogeneous in
their ability to recognize different mCD1
 
1
 
 cell lines and
transfectants (20, 21). These data suggest that a diverse set
of autologous ligands may be presented by mCD1, al-
though other interpretations are not ruled out. Consistent
with the requirement for a diverse set of ligands, it has been
shown recently that mouse V
 
a
 
14
 
1
 
 T cells can recognize
the lipoglycan 
 
a
 
-galactosylceramide (
 
a
 
-GalCer) presented
by mCD1, whereas V
 
a
 
14
 
2
 
 but mCD1-autoreactive T cells
are not responsive to this antigen (22, 23).
In this study, we have uncovered a surprising degree of
conservation in the interaction of invariant NK TCRs
from different species with CD1 molecules despite the ex-
tensive divergence in primary sequences of these molecules
between mice and humans. We also demonstrate here that
 
a
 
-GalCer is presented by hCD1d to human NK T cells,
providing the first evidence both for the presentation of a
defined antigen by hCD1d and for a requirement for hu-
man NK T cells for a lipoglycan antigen in addition to
hCD1d. As 
 
a
 
-GalCer can induce a dramatic hCD1d de-
pendent expansion of human NK T cells, as well as a strong
release of cytokines by these cells, our data further suggest
that this lipoglycan could be a useful agent for the modula-
tion of human immune responses.
 
Materials and Methods
 
Gene Cloning and Transfection.
 
pSR
 
a
 
-neo-hCD1d (a gift from
Dr. S. Balk, Beth Israel Hospital, Boston, MA), which contains a
full-length hCD1d cDNA, was used as a template for PCR. After
amplification, the hCD1d cDNA was sequenced and ligated into
the TA cloning vector (InVitrogen, Carlsbad, CA). For expres-
sion in mammalian cells, the hCD1d cDNA was inserted into the
BamHI and SalI sites of the pH
 
b
 
Aprneo vector, which contains
the human 
 
b
 
-actin promoter. 20 
 
m
 
g of plasmid was linearized
and electroporated (Gene Transfector 300, BTX Corp., San Di-
ego, CA) into A20 B lymphoma, C1R, and Hela cells. Stable
transfectants were chosen at 3–4 wk and stained with biotinylated
anti-hCD1d mAb 42.2 (see below).
 
T Cell Hybridomas.
 
The derivation and characterization of
the mCD1 autoreactive T cell hybridomas has been described
previously (21, 23, 24). For the stimulation assays, 5 
 
3
 
 10
 
4
 
 T hy-
bridoma cells per well were cultured in the presence of 10
 
5
 
mCD1
 
1
 
, hCD1d
 
1
 
, or control stimulator cells. After 16 h, IL-2
 
release was evaluated in a sandwich ELISA using rat anti–mouse
IL-2 mAbs (PharMingen, San Diego, CA).
 
Cloning of Invariant V
 
a
 
24
 
1
 
 T Cells.
 
PBMCs of healthy do-
nors were stained with purified anti-V
 
a
 
24 (IgG1) and anti-V
 
b
 
11
(IgG2a) mAbs, followed by human adsorbed FITC-conjugated
goat anti–mouse IgG1 and PE-conjugated goat anti–mouse
IgG2a antibodies (Southern Biotechnology Associates, Inc., Bir-
mingham, AL). Double positive cells were sorted and either im-
mediately cloned by limiting dilution or activated as a primary
bulk culture and then cloned by limiting dilution (14). Clones
that coexpressed V
 
a
 
24 and V
 
b
 
11 by cytofluorimetric analysis
were further expanded and used for this study. Molecular typing
of the TCR expressed by V
 
a
 
24/V
 
b
 
11
 
1
 
 T cell clones was per-
formed as previously described (25).
 
Activation of V
 
a
 
24/V
 
b
 
11
 
1
 
 T Cell Clones by CD1 Transfec-
tants.
 
Activations were performed in 96-well plates in 200 
 
m
 
l
total volume containing 1 ng/ml of PMA. T cell clones were
added to wells at 5 
 
3 
 
10
 
4
 
 per well, along with 10
 
5
 
 CD1 transfec-
tants. Hela and Hela-hCD1d transfectants were fixed for 30 s in
glutaraldehyde 0.05% in PBS, immediately diluted, and washed
three times in complete medium. Antigen-pulsed APCs were
generated by culture of hCD1d transfectants for 2 h with 100 ng/
ml of 
 
a
 
-GalCer followed by three washes, and irradiated at 8,500
rads. To block recognition of hCD1d, the 51.1 anti-hCD1d–spe-
cific mAb, provided by Dr. S. Porcelli (Brigham and Women’s
Hospital, Boston, MA), or control irrelevant mouse IgG2b was
added to cultures at a final concentration of 20 
 
m
 
g/ml.
 
Generation of 
 
a
 
-GalCer–reactive Cell Lines.
 
Total human PBMCs
were cultivated in 24-well plates in the presence of 50 U/ml of
IL-2 and 100 ng/ml of 
 
a
 
-GalCer. Expansion of the V
 
a
 
24
 
1
 
 cells
was determined upon staining with a combination of anti-CD3,
anti-CD4, anti-CD8, anti-V
 
a
 
24, and anti-V
 
b
 
11 mAbs.
 
Flow Cytometric Analysis.
 
Biotinylated anti-hCD1d mAb 42.2
was provided by Dr. S. Porcelli. Secondary reagents for mCD1
detection were streptavidin-PE–conjugated (Caltag, South San
Francisco, CA). For staining, cells were suspended in buffer
comprised of PBS, pH 7.3, containing 2% BSA (wt/vol) and
0.02% NaN3 (wt/vol) and incubated at 4
 
8
 
C for 20–30 min with
the primary Ab, washed twice, and then further incubated with
secondary reagents for another 20–30 min at 4
 
8
 
C. After two
washes, the cells were fixed and analyzed on a FACScan
 
Ò
 
 440
flow cytometer (Becton Dickinson, San Jose, CA).
 
Cytokine Determination by ELISA.
 
Supernatants were quanti-
fied for IL-4 or IFN-
 
g
 
 by ELISA using commercial pairs of
mAbs: BAF285 and MAB285 for IFN-
 
g
 
 or BAF 204 and
MAB604 for IL-4 (R&D Systems, Minneapolis, MN).
 
Results
 
A Subset of mCD1–autoreactive Hybridomas Responds to
hCD1d.
 
The parallels between mouse and human NK T
cells led us to test for a possible cross-reactivity of mouse T
cell hybridomas with hCD1d. Transfectants in several dif-
ferent cell types were generated and selected for approxi-
mately similar levels of surface hCD1d expression (Fig. 1
A). Each of these three transfected cell lines was used as
APCs for T cell hybridomas that are mCD1 autoreactive.
As shown in Table 1, two of the seven mCD1 autoreactive
hybridomas also react with the three different hCD1d
transfectants, whereas the other five do not. The hCD1d
reactivity of these two NK T cell hybridomas has been1523 Brossay et al.
confirmed using anti-hCD1d blocking mAb, which inhib-
ited the reactivity to hCD1d A20 transfectants but not to
mCD1 transfectants of the same cell line (Fig. 1 B). Similar
antibody blocking data have been obtained using hCD1d-
transfected Hela and C1R cells (data not shown).
It is noteworthy that the two hCD1d reactive mouse T
cell hybridomas express the canonical Va14/Vb8 NK
TCR, whereas the nonreactive ones either express Va14/
Vb8 or Va14/Vb10 or, in three instances, lack Va14 ex-
pression. The lack of hCD1d reactivity of the Va14/Vb81
3C3 hybridoma is not due to a lower level of TCR expres-
sion, implicating either Vb junctional sequences or some
other factor that distinguishes this hybridoma. Surprisingly,
one of the two cross-reactive T cell hybridomas, DN3A4-
1-2, responds much more strongly to hCD1d than to
mCD1 transfectants of A20 cells (Table 1 and Fig. 1 B). Al-
though the amount of IL-2 this cell releases in response to
mCD1 transfectants is well above the background, the
z12-fold greater increase in IL-2 release obtained with
hCD1d was typical of the results from nine different exper-
iments. By contrast, hybridoma 2C12 reacts equally to the
two CD1 homologues (Table 1 and Fig. 1 B).
A Subset of Human NK T Cell Clones Are Reactive to
mCD1 Molecules. We then asked whether the interspecies
cross-reactivity of NK T cells for CD1 molecules also
would be observed using human Va24/Vb111 clones as
responder cells. The presence or absence of the invariant
Va24-JaQ rearrangement in the T cell clones was con-
firmed by both heteroduplex and oligotyping analysis, and
the diversity in the Vb11 junctions was determined by se-
quencing (data not shown). A total of six clones from three
different donors were analyzed, four of which expressed
the invariant Va24 TCR paired with Vb11 and two of
which expressed a noninvariant Va24 also paired with
Vb11. The ability of these clones to release IFN-g (Table
2) and IL-4 (data not shown) in response to CD1 transfec-
tants was tested. Data from five experiments are combined
and averaged. Consistent with previous data (11), we found
that recognition of hCD1d by human NK T cells required
PMA, and in some cases also required mild aldehyde fixa-
tion of the target cells. Therefore, all the experiments
shown in Table 2 had PMA in the cultures, and the Hela
cell APCs also were fixed with glutaraldehyde.
In agreement with the previous results, all of the clones
with an invariant Va24 TCR could respond either to one
or both hCD1d transfectants (Table 2). As we and others
have described for mouse NK T cells (20, 21), the reactiv-
ity of different human NK T cell clones is somewhat heter-
ogeneous, and is more dependent on the type of hCD1d
expressing APCs than on the level of hCD1d surface ex-
pression. Indeed, clone LG2D3 responds to hCD1d-trans-
Figure 1. hCD1d stimulates mouse NK T cell hybridomas. (A) Flow
cytometry profiles of hCD1d-transfected A20, Hela, and C1R cell lines.
Stainings were carried out with biotinylated 42.2 anti-hCD1d mAb, fol-
lowed by PE-conjugated streptavidin. Before each staining, cells were in-
cubated with 1% human serum. Each panel is an overlay of the isotype
control (open histogram) and the anti-hCD1d mAb (filled histogram). (B) In-
terspecies cross-reactivity of mouse Va14/Vb8 T cell hybridomas. The
2C12 and DN3A4-1.2 mCD1-autoreactive hybridomas were cultured at
5 3 104 cells/well with 105 APCs. Antibody-mediated inhibition was de-
termined using an anti-hCD1d mAb 51.1, anti-mCD1 mAb 1B1, or iso-
type-matched control mAbs, all at 10 mg/ml. After 16 h of culture, IL-2
release was determined by ELISA. The experiments shown here are rep-
resentative of nine different experiments.
Table 1. A Subset of mCD1-restricted T Cells Responds to hCD1D Molecule
Hybridoma TCR A20 mock A20 mCD1 A20 hCD1d Hela Hela hCD1d C1R C1R hCD1d
24 a3.2/b9 0.1* 22.3 0.2 0.1 0.1 0.1 0.1
1A12 a5/b14 0.2 40.1 0.1 0.1 0.1 0.1 0.1
68 a4/b11 0.3 6 0.3 0.1 0.2 0.1 0.1
DN3A4-1-4 a14/b10 0.4 6.4 0.2 0.1 0.1 0.1 0.1
2C12 a14/b8 0.1 74.6 97.6 0.1 4 0.1 27
DN3A4-1-2 a14/b8 0.1 20 239 0.1 7.6 4.2 99
3C3 a14/b8 0.1 4 0.1 0.1 0.1 0.1 0.1
*IL-2 release is expressed in units per milliliter and determined according to the IL-2 standard from PharMingen.1524 CD1 Presentation of a-Galactosylceramide
fected Hela cells but not to A20-transfected cells, whereas
the other three clones respond similarly to both types of
cells (Table 2). Neither of the two clones that lack the in-
variant Va24 responded significantly to the hCD1d trans-
fectants, although both showed some background reactivity
against all the APCs when PMA was added. When reac-
tive, each of the clones could synthesize significant quanti-
ties of both IFN-g and IL-4 in response to hCD1d stimula-
tion.Three out of the four clones with an invariant Va24
also were stimulated significantly by transfectants expressing
heterologous mCD1 in the presence of PMA (Table 2),
and this reactivity could be inhibited with an anti-mCD1
mAb (data not shown).
In summary, we conclude that not only have NK T cells
been conserved throughout evolution, but the ability of the
invariant TCR expressed by NK T cells to recognize the
CD1d-like molecules mCD1 and hCD1d also has been
conserved strictly. Furthermore, if self-ligands are required
for this CD1 recognition, these ligands are likely to be sim-
ilar in mice and humans.
Mouse Va14/Vb81 Hybridomas Respond to a-GalCer–
pulsed hCD1d Molecules. We tested the ability of mouse
NK T cell hybridomas to respond to the lipoglycan a-Gal-
Cer presented by the heterologous hCD1d molecule. It has
been shown recently that mouse NK T cells with an invari-
ant Va14 TCR can respond in an mCD1-mediated fashion
to a-GalCer (22, 23). We therefore used this compound to
determine if hCD1d and mCD1 can present similar com-
pounds to NK T cells.
Using a-GalCer–pulsed CD1d transfectants as APCs, we
analyzed the reactivity of the panel of seven mouse T cell
hybridomas described in Table 1. Only three hybridomas
responded to the pulsed APCs, regardless of whether the
hCD1d-expressing cell line used was a transfected C1R,
A20, or Hela cell. The responses of Va14/Vb81 hybrido-
mas 2C12 and DN3A4-1-2 to hCD1d plus a-GalCer were
significantly increased above the level of hCD1d reactivity
in the presence of the vehicle alone. Depending upon the
APC used, the ratio of the IL-2 production in the presence
of  a-GalCer compared with the vehicle increased from
1.7- to 3-fold for hybridoma 2C12, and from 1.5- to 9.6-
fold for hybridoma DN3A4-1-2. Interestingly, although
the third Va14/Vb81 hybridoma, 3C3, was unresponsive
to hCD1d transfectants in the absence of antigen, it was
strongly stimulated by a-GalCer–pulsed hCD1d cells (Fig.
2 A). Complete inhibition of the IL-2 release induced by
a-GalCer pulsed APCs was obtained using an anti-hCD1d
mAb, confirming the hCD1-mediated presentation of
a-GalCer (Fig. 2 A). Therefore, all three Va14/Vb81 T
cell hybridomas tested respond to hCD1d plus a-GalCer.
By contrast, the Va14/Vb101 hybridoma DN3A4-1-4 re-
sponded to a-GalCer–pulsed mCD1-expressing APCs but
not to a-GalCer–pulsed hCD1d-expressing cells (Fig. 2 B).
In summary, these data demonstrate that hCD1d can present
the same lipoglycan antigen as its mouse counterpart. Our
previous studies demonstrated that mCD1-mediated recog-
nition of a-GalCer by mouse NK T cells was effective when
Va14 was expressed with any one of these different TCR-b
chains (23). The data presented here, in contrast, suggest that
when presented by the heterologous hCD1d molecule
a-GalCer responsiveness by mouse NK T cells may be more
highly dependent upon the TCR-b chain.
Human Invariant Va24/Vb111 Clones Respond to a-Gal-
Cer–pulsed hCD1d Molecules. We next tested if human NK
Table 2. Invariant Va241 T Cell Clones Respond to
mCD1-transfected Cells (IFN-g)
Clones TCR A20
A20
mCD1
A20
hCD1d Hela
Hela
hCD1d
PD9 I* 230‡ 1,050 620 50 1,300
PD16 I 430 1,500 1,280 0 1,590
LG2D3 I 0 0 0 0 1,080
15.21.2 I 0 690 510 0 220
15.21.3 NI 370 280 94 2,500 770
PD18 NI 600 460 700 330 370
*I, invariant Va24/Vb11 TCR; NI, noninvariant Va24/Vb11 TCR.
‡IFN-g release is expressed in picogram per milliliter and determined
according to the IFN-g standard from R & D.
Figure 2. hCD1d presents a-GalCer to mouse and human NK T cells.
(A and B) Response of a Va14/Vb8 hybridoma. hCD1d-transfected cells
(A20 hCD1d), mCD1.1-transfected cells (A20 mCD1), or untransfected
A20 cells were pulsed for 2 h either with a-GalCer or the vehicle control.
These APCs were washed twice and plated at 105 cells/well. Antibodies at
10 mg/ml were added immediately before the addition of either the 3C3
(Va14/Vb8) or the DN3A4-1-4 (Va14/Vb10) T cell hybridomas at 5 3
104 cells/well. After 16 h of culture, IL-2 release was determined by
ELISA. The experiments shown here are representative of four different
experiments. (C) Response of a human Va24/Vb11 clone. hCD1d CIR
transfectants (C1R hCD1d), hCD1d-transfected Hela cells (Hela
hCD1d), or the untransfected parental control cells were antigen pulsed as
described above. Cells were then incubated for 48 h with T cells from
clone 15.21.2 at 5 3 104 cells/well. Isotype-matched control or anti-
hCD1d mAb 51.1 at 20 mg/ml were added immediately before the addi-
tion of the T cells. IFN-g and IL-4 release were determined by ELISA.
The experiments shown here have been performed without the addition
of PMA, and they are representative of three different experiments.1525 Brossay et al.
T cell clones are responsive to a-GalCer presented by
hCD1d. Cultures containing lipoglycan antigen-pulsed
APC were carried out in the absence of either PMA or glu-
taraldehyde fixation. Three NK T cell clones with an in-
variant Va24 TCR (15.21.2, LG2D3, and PD9) and one
of the Va24/Vb11 clones without the invariant junction
(PD18) were tested. In the absence of lipoglycan antigen
there was no stimulation by hCD1d because of the absence
of PMA. The results from one representative experiment of
three carried out with clone 15.21.2 are shown in Fig. 2 C.
a-GalCer is a potent inducer of both IFN-g and IL-4
release by this T cell clone. The cytokine release was in-
hibited by an anti-hCD1d mAb (Fig. 2 C) as well as an
anti-Va24 mAb (data not shown), confirming the TCR-
mediated recognition of a-GalCer–pulsed hCD1d1 APCs.
Similar data were obtained with clones LG2D3 and PD9.
The reactivity of the 15.21.2 and PD9 human T cell clones
for heterologous mCD1 also could be detected by the
addition of a-GalCer. Clone LG2D3, which did not
respond to mCD11 APCs in the presence of PMA, like-
wise did not respond to a-GalCer presented by mCD1
(data not shown).
a-GalCer–induced Expansion of Human Primary NK T
Cells. The results described above demonstrate that long
term T cell clones, selected only on the basis of invariant
Va24 and Vb11 expression, are specifically activated by
a-GalCer presented by hCD1d. To analyze the response of
T cells that have not been subject to long-term culture, we
asked whether a-GalCer would induce the in vitro prolif-
eration of human NK T cells. In these experiments, either
the lipoglycan antigen or the vehicle control was added di-
rectly to cultures of unfractionated, fresh PBMCs. The per-
centage of Va24-positive T cells was determined by flow
cytometry at days 0, 7, 9, 11, and 12. By day 12, we sys-
tematically obtained a significant expansion in both the
percentage and number of T cells expressing the Va24/
Vb11 TCR. A compilation of all the data from a series of
experiments done with PBMCs from eight different donors
is shown in Table 3. Although on day 0 the Va24/Vb111
T cells were ,1% of the total cell number, by day 7–12,
the percentage of Va241 cells had expanded from 18.5- to
82-fold (Table 3). This increase in the percentage of
Va241 cells is due to an expansion in cell number, because
the total number of cells in the cultures generally was not
decreased compared with day 0. This expansion required
the presence of IL-2 and a-GalCer, as the number of
Va24/Vb111 T cells did not augment significantly when
either one of these reagents was omitted (data not shown).
PCR-heteroduplex analysis and oligotyping performed on
aliquots of PBMCs, drawn at different time points from the
different culture conditions, confirmed the expansion of
Va24/Vb111 T cells expressing the invariant Va24-JaQ
rearrangement (data not shown). Several of these lines were
maintained in culture beyond day 12, and restimulated
once with a-GalCer–pulsed autologous APCs, and fur-
ther with a-GalCer–pulsed hCD1d-transfected C1R cells.
These two further recalls allowed us to enrich the percent-
age of Va24-positive T cells to 64% for line XC and 53%
for line PB (Fig. 3). As shown in Fig. 3, lipoglycan-specific
invariant Va24/Vb111 T cells are either CD41 or CD42,
consistent with previous reports on the surface phenotype
of this subset (12, 14, 16). A 72% inhibition of the expan-
sion of Va241 T cells was obtained for line PB when paral-
lel cultures were set up from day 0 in the presence of the
51.1 anti-hCD1d mAb. This inhibition is consistent with
the view that the a-GalCer–induced expansion of fresh T
cells is hCD1d dependent. Similarly, a 62 and 60% reduc-
tion of the Va241 T cell expansion was obtained for lines
MP and PD, respectively, when an anti-Va24 mAb was
added to the culture from day 0. These data suggest that
the a-GalCer–induced T cell expansion was dependent
upon engagement of the TCR. Interestingly, when cul-
tured in the presence of a-GalCer–pulsed transfected
Table 3. a-GalCer Induces Expansion of Va24/Vb111 T Cells
Cell line Day 0 Antigen-stimulated*
PD 0.2‡ 5 (25)§
MP 0.08 2.7 (33)
CRG 0.06 3.4 (57)
BG 0.35 20 (57)
CU 0.13 8.6 (66)
XC 0.39 32.1 (82)
YG 0.45 8.17 (18.5)
PB 0.28 12.8 (45.7)
*Stainings were done at day 7, 9, 11, or 12 depending on the donor.
‡Percentage of Va241 T cells within CD31 T cells.
§Fold of expansion over percentage of input.
Figure 3. NK T cells from human PBMCs expand in response to
a-GalCer. Crude PBMCs were cultivated in the presence of 50 U/ml of
IL-2 and 100 ng/ml of a-GalCer. At day 10 harvested cells from XC cell
line (top) or PB cell line (bottom) were cultured for 5 d in the presence of
IL-2 only. Proliferating T cells were then cultured for another 5 d with
a-GalCer pulsed C1R-hCD1d transfectants in the presence of 50 U of
IL-2. Expansion of the Va241 cells was determined upon staining with
anti-CD4 and anti-Va24 mAbs at days 0, 9, and 21.1526 CD1 Presentation of a-Galactosylceramide
APCs, these 2 lines released IFN-g but not IL-4 in an
hCD1d- and Va24-dependent manner (data not shown).
Discussion
The hCD1d molecule is of particular interest on account
of its recognition by human NK T cells and on account of
having a broader expression pattern than do other human
CD1 molecules (26). In this report, we provide the first ev-
idence for the ability of hCD1d to present antigen. The an-
tigen identified here is a-GalCer, a structurally well-defined
glycolipid. In the presence of a-GalCer, neither the addi-
tion of PMA nor fixation of the APCs is required to stimulate
NK T cell reactivity to hCD1d. Furthermore, preliminary
data indicate that a-GalCer can bind in vitro to purified,
soluble hCD1d and mCD1 molecules (Maher, J., O. Naid-
enko, W. Ernst, R. Modlin, and M. Kronenberg, manu-
script in preparation). Together with the antigen presenta-
tion and antibody inhibition studies presented here, these
data indicate that the effect of a-GalCer is not likely to be
an indirect one, but rather that a-GalCer forms a complex
with hCD1d that is recognized by the TCR on human NK
T cells. It should be noted that a-GalCer was purified from
an extract from a marine sponge, based upon the positive
results obtained with this extract during a screen for com-
pounds that prevent tumor metastases (27). Ceramides with
an a-linked sugar are not abundant in most microbes, and
they are much less abundant than those with a b-linked
sugar in mammalian cells. However, b-galactosylceramide
is not an antigen for CD1d presentation (22, 23). It there-
fore remains possible that a-GalCer is a mimic for a natural
ligand that normally stimulates NK T cells, although there
are no data to exclude the possibility of a low level of
a-GalCer expression in mammalian cells. In mice, a glyco-
sylphosphatidylinositol has been the only natural ligand
bound to mCD1 identified so far (28), although com-
pounds of this type apparently do not stimulate NK T cells
in a CD1-dependent fashion (23).
The lack of polymorphism of nonclassical antigen-pre-
senting molecules has led to the proposal that they may
carry out some conserved and essential antigen presenting
function. Although this is a plausible hypothesis, with the
possible exception of mouse Qa-1b and human HLA-E
(29), there is surprisingly little evidence for interspecies
conservation of nonclassical class I molecules at either the
sequence level or the functional level. In contrast, the CD1
family is demonstrated here to show an extremely high de-
gree of conservation with regard to its interaction with the
invariant TCRs that are expressed by NK T cells. This
conservation is observed either in the absence of exogenous
antigen or together with a lipoglycan antigen. From a func-
tional viewpoint, the mouse and human invariant TCRs
and CD1 molecules are nearly equivalent, indicating a
strong selection upon this TCR interaction with CD1.
These data are consistent with previous reports demonstrat-
ing that human and mouse NK T cells are similar in phe-
notype and function (11, 12, 16). This degree of conserva-
tion and cross-reactivity at the antigen recognition level is
particularly striking in light of the divergence in primary
sequence of both the CD1 molecules and the TCRs ex-
pressed by NK T cells (5). We conclude that despite these
significant changes in primary structure, the amino acids
important for either lipoglycan binding to CD1 or the in-
teraction between the TCR and CD1 must not have di-
verged significantly.
The results from immune assays of mouse and human T
cells permit the identification of candidate regions of the
TCR that are necessary for the recognition of CD1 plus li-
poglycan. Data from a previous study of TCR transgenic
mice expressing Vb8 and Va14 and of mice deficient for
Ja281 as a result of targeted mutation implicated a role for
the invariant Va14 TCR in a-GalCer recognition (22).
Although several analyses of mCD1-reactive T cell hybrid-
omas and cell lines established that Va14 is not absolutely
required for mCD1 autorecognition (20, 24, 30), only
mCD1-autoreactive hybridomas with a Va14 TCR could
respond to a-GalCer plus mCD1 (23). The conservation of
the Va-Ja junction in the invariant TCR (14, 15, 18, 31)
implicates this region of the TCR in contacting the CD1
molecule or a combination of CD1 and lipoglycan bound
to it. Consistent with this hypothesis, we found that human
T cells that express a Va24 without the invariant V-J junc-
tional sequence were unreactive to hCD1d transfectants in
either the absence or presence of a-GalCer. Furthermore,
there may be a more stringent selection upon the NK T
cell b chain in humans than in mice, as the invariant Va24
is mainly paired with Vb11 (16, 32, 33), whereas in mice
there are several predominant Vbs (12, 19, 20).
It is unprecedented to find complete cross-reactivity be-
tween mice and humans of the interaction of a TCR with
a peptide–MHC complex. However, such a high degree of
conservation is consistent with a superantigen type of rec-
ognition mechanism (34). In addition, the high frequency
of a-GalCer–reactive cells in humans is consistent with a
superantigen-like mode of action. However, there are two
reasons why the data presented here do not favor the possi-
bility that a-GalCer is recognized as a superantigen. First,
the reactive T cells have a restricted V-J junctional diversity
of their a chains, as well as Va gene use. Second, the reac-
tive T cells are selected for both Va and for Vb expression,
particularly in humans. These findings favor a more con-
ventional mechanism for the interaction of the a-GalCer
plus CD1 complex with the TCR expressed by NK T
cells.
At the functional level, NK T cells are distinguished by
their ability to produce large amounts of the cytokines
characteristic of memory T cells within a few hours of
stimulation. It was proposed originally that the early ex-
pression of IL-4 by NK T cells could be required for Th2-
type immune responses (35–36). Although NK T cells nor-
mally may contribute to the induction of Th2 responses, it
is now clear that in many cases they are not required (37,
38). It also is clear from our studies and those of other in-
vestigators that NK T cells can secrete large amounts of
IFN-g in addition to IL-4 under some circumstances (39,
40). Based upon their relatively high frequency in some1527 Brossay et al.
sites and their ability to rapidly secrete large amounts of cy-
tokines, functions for NK T cells in the regulation of au-
toimmune diseases (33, 41, 42), the response to infectious
agents (43), and the surveillance for tumors (44) have been
proposed. With regard to autoimmune disease progression,
the strongest evidence currently favors a connection be-
tween NK T cells and diabetes, in which the results from
mice and humans show a striking degree of similarity (33,
42, 45). The dramatic expansion and activation of human
NK T cells upon stimulation in vitro with a-GalCer is
therefore of a considerable interest. Because we generally
observed both IL-4 and IFN-g in the culture supernatants
of the T cell clones, but only IFN-g from the lines, it
should be possible to identify conditions in which a more
polarized cytokine response develops. Therefore, one
might envision the use of this molecule, or perhaps ana-
logues (22) that might give a more polarized Th1 or Th2
response, as an attractive strategy to modulate human im-
mune response in vivo.
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